Scholar Rock Holding Corp at JPMorgan Healthcare Conference TranscriptJan 09, 2024- Q3 2023 Scholar Rock Holding Corp Earnings Call TranscriptNov 07, 2023$12.35 (+1.48%)Earnings
- Scholar Rock Holding Corp Overview of the Current Treatment Landscape and Unmet Needs of Patients with SMA TranscriptJul 12, 2023
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Scholar Rock Holding Corp TOPAZ Phase 2 Clinical Trial Data TranscriptJun 17, 2022
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Scholar Rock Holding Corp at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 09, 2021
- Scholar Rock Holding Corp to Host KOL Discussing Apitegromab's Therapeutic Potential in Patients with SMA Call TranscriptJun 15, 2021
- Scholar Rock Holding Corp at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Scholar Rock Holding Corp Annual Shareholders Meeting TranscriptMay 27, 2021
- Scholar Rock Holding Corp to Announce the 12-Month Top-line Results of TOPAZ Phase 2 Trial TranscriptApr 06, 2021
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Scholar Rock Holding Corp to Discuss the SRK-015 TOPAZ Interim Analysis Results Conference Call TranscriptOct 27, 2020
- Scholar Rock Holding Corp at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- Q2 2020 Scholar Rock Holding Corp Earnings Call TranscriptAug 07, 2020$14.07 (+2.25%)Earnings
- Scholar Rock Holding Corp Annual Shareholders Meeting TranscriptMay 29, 2020
- Scholar Rock Holding Corp at Morgan Stanley Healthcare Conference TranscriptSep 11, 2019
- Scholar Rock Holding Corp at Oppenheimer Healthcare Conference TranscriptMar 19, 2019
- Scholar Rock Holding Corp at Cowen Health Care Conference TranscriptMar 13, 2019
- Scholar Rock Holding Corp SRK-015 Interim Phase 1 Results and Phase 2 Trial Design Conference Call TranscriptFeb 26, 2019
Scholar Rock Holding Corp at Cowen Health Care Conference Transcript
Good morning, everyone. Thanks for joining us today on the last day of Cowen's 39th Annual Healthcare Conference here in Boston. I am covering biotech analyst, Ritu Baral, and welcome to the Scholar Rock corporate presentation. Presenting on behalf of Scholar Rock is President and CEO, Nagesh Mahanthappa. Nagesh, take it away.
Thank you, Ritu. So yes, I am new Nagesh Mahanthappa, President and CEO of Scholar Rock and I'd like to thank Cowen for the opportunity to present today. The obligatory disclaimer slide. Again, details on risk factors can be found in our most recent 10-Q filings.
With that let me turn to the foundation that we've created over the last year which really sets the stage for a number of very exciting activities this year. So 2018 was a very exciting year for us. The Company went public in May raising $86 million in gross proceeds. Within days of initiating that IPO process we also became a clinical stage company putting
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
